



## Clinical trial results:

Randomised, multicentre, unblinded, phase III trial evaluating HBsAg loss at W96 following 48 weeks of treatment with pegulated interferon alpha-2a in patients with chronic hepatitis B (HBeAg-negative), on treatment and responders (undetectable viral load) to nucleoside analogue(s) and/or nucleotide analogue(s) therapy for at least 12 months.

### Summary

EudraCT number	2010-019367-11
Trial protocol	FR
Global end of trial date	23 September 2015

### Results information

Result version number	v1 (current)
This version publication date	08 December 2023
First version publication date	08 December 2023

### Trial information

#### Trial identification

Sponsor protocol code	ANRS HB 06 PEGAN
-----------------------	------------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01170392
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Inserm-ANRS
Sponsor organisation address	101 rue de Tolbiac, Paris, France, 75013
Public contact	Dr. Yves BENHAMOU, Service d'hépatogastroentérologie, +33 1 42 16 10 21, ybenhamou@teaser.fr
Scientific contact	Dr. Marc BOURLIERE, Service d'hépatogastroentérologie, +33 4 91 80 66 08, mbourliere@hopital-saint-joseph.fr

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 December 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 September 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Evaluation of patients with HBsAg negative at W96 following 48 weeks of treatment with pegulated interferon alpha-2a.

Protection of trial subjects:

This study is conducted in accordance with the updated Declaration of Helsinki, in compliance with the approved protocol and its amendments, the International Council for Harmonisation guideline for Good Clinical Practice (ICH GPC), and French regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 January 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 183
Worldwide total number of subjects	183
EEA total number of subjects	183

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	179
From 65 to 84 years	4
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

From January 2011 to September 2012, 401 participants were screened from 34 centres in France.

### Pre-assignment

Screening details:

Main criteria:

Inclusion: age between 18 - 75 years old, HBsAg positive, HBeAg negative.

Non inclusion: polynuclear neutrophils < 1500 mm<sup>3</sup>, platelets < 70 000/mm<sup>3</sup>, HIV, HCV and/or HDV co-infections.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	PegIFN + analogue(s)

Arm description:

92 patients were first randomised in this arm. 2 patients were excluded from the analysis (1 withdrawal of consent and 1 breach of inclusion criteria).

Arm type	Experimental
Investigational medicinal product name	Pegylated-interferon alpha-2a
Investigational medicinal product code	
Other name	Pegasys
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Dose: 180 µg/week.

Storage: between +2°C and +8°C, protected from light.

Investigational medicinal product name	Analogues
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dosage and administrations details depends on the patient's ongoing treatment (Entecavir, Tenofovir, Adefovir and/or Lamivudine)

<b>Arm title</b>	Analogue(s) alone
------------------	-------------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Analogues
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Dosage and administrations details depends on the patient's ongoing treatment (Entecavir, Tenofovir, Adefovir and/or Lamivudine)

<b>Number of subjects in period 1</b>	<b>PegIFN + analogue(s)</b>	<b>Analogue(s) alone</b>
Started	90	93
Completed	65	93
Not completed	25	0
Discontinuation	4	-
Adverse event, non-fatal	16	-
Had PegIFN dose reduction	3	-
Lack of compliance	1	-
Lost to follow-up	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	PegIFN + analogue(s)
-----------------------	----------------------

Reporting group description:

92 patients were first randomised in this arm. 2 patients were excluded from the analysis (1 withdrawal of consent and 1 breach of inclusion criteria).

Reporting group title	Analogue(s) alone
-----------------------	-------------------

Reporting group description: -

Reporting group values	PegIFN + analogue(s)	Analogue(s) alone	Total
Number of subjects	90	93	183
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
median	47	48	
inter-quartile range (Q1-Q3)	41 to 57	39 to 54	-
Gender categorical Units: Subjects			
Female	15	10	25
Male	75	83	158

## End points

### End points reporting groups

Reporting group title	PegIFN + analogue(s)
Reporting group description: 92 patients were first randomised in this arm. 2 patients were excluded from the analysis (1 withdrawal of consent and 1 breach of inclusion criteria).	
Reporting group title	Analogue(s) alone
Reporting group description: -	

### Primary: HBsAg loss

End point title	HBsAg loss
End point description:	
End point type	Primary
End point timeframe: This endpoint was assessed at week 96.	

End point values	PegIFN + analogue(s)	Analogue(s) alone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	90	93		
Units: Patients	7	3		

Attachments (see zip file)	HBsAg-W96-loss/PEGAN_HBsAg-loss.png
----------------------------	-------------------------------------

### Statistical analyses

Statistical analysis title	Loss of HBsAg at week 96
Comparison groups	Analogue(s) alone v PegIFN + analogue(s)
Number of subjects included in analysis	183
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.15
Method	Cochran-Mantel-Haenszel

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

During the entire period of follow-up.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	PegIFN + analogue(s)
-----------------------	----------------------

Reporting group description: -

Reporting group title	Analogue(s) alone
-----------------------	-------------------

Reporting group description: -

Serious adverse events	PegIFN + analogue(s)	Analogue(s) alone	
Total subjects affected by serious adverse events			
subjects affected / exposed	19 / 90 (21.11%)	6 / 93 (6.45%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	1	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatic neoplasm malignant			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular carcinoma			

subjects affected / exposed	2 / 90 (2.22%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Malignant peritoneal neoplasm			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Renal artery stenosis			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Shoulder operation			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Caesarean section			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	1 / 90 (1.11%)	2 / 93 (2.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	



Normal newborn subjects affected / exposed	2 / 90 (2.22%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Malaise			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Lung disorder			
subjects affected / exposed	2 / 90 (2.22%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 90 (4.44%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gamma-glutamyltransferase			

increased			
subjects affected / exposed	3 / 90 (3.33%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	5 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Radius fracture			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cervical myelopathy			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			

subjects affected / exposed	4 / 90 (4.44%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	6 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abnormal faeces			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic artery aneurysm			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			

subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	1 / 90 (1.11%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	2 / 90 (2.22%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Calculus urinary			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Diabetes insipidus			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Rotator cuff syndrome			
subjects affected / exposed	1 / 90 (1.11%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Erysipelas			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			

subjects affected / exposed	1 / 90 (1.11%)	0 / 93 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute HIV infection			
subjects affected / exposed	0 / 90 (0.00%)	1 / 93 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	PegIFN + analogue(s)	Analogue(s) alone	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	85 / 90 (94.44%)	89 / 93 (95.70%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatic neoplasm			
subjects affected / exposed	7 / 90 (7.78%)	0 / 93 (0.00%)	
occurrences (all)	7	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 90 (2.22%)	8 / 93 (8.60%)	
occurrences (all)	3	8	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	67 / 90 (74.44%)	17 / 93 (18.28%)	
occurrences (all)	84	17	
Influenza like illness			
subjects affected / exposed	36 / 90 (40.00%)	3 / 93 (3.23%)	
occurrences (all)	38	3	
Injection site erythema			
subjects affected / exposed	6 / 90 (6.67%)	0 / 93 (0.00%)	
occurrences (all)	7	0	
Pyrexia			
subjects affected / exposed	12 / 90 (13.33%)	0 / 93 (0.00%)	
occurrences (all)	13	0	
Immune system disorders			

Bronchitis subjects affected / exposed occurrences (all)	7 / 90 (7.78%) 8	4 / 93 (4.30%) 4	
Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all)	6 / 90 (6.67%) 6	1 / 93 (1.08%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Productive cough subjects affected / exposed occurrences (all)	15 / 90 (16.67%) 16  5 / 90 (5.56%) 5  6 / 90 (6.67%) 6  6 / 90 (6.67%) 6	5 / 93 (5.38%) 5  1 / 93 (1.08%) 1  2 / 93 (2.15%) 2  2 / 93 (2.15%) 2	
Psychiatric disorders Attention deficit hyperactivity disorder subjects affected / exposed occurrences (all)  Depression subjects affected / exposed occurrences (all)  Insomnia subjects affected / exposed occurrences (all)  Irritability subjects affected / exposed occurrences (all)  Sleep disorder	6 / 90 (6.67%) 6  5 / 90 (5.56%) 7  10 / 90 (11.11%) 11  13 / 90 (14.44%) 14	0 / 93 (0.00%) 0  3 / 93 (3.23%) 3  2 / 93 (2.15%) 3  1 / 93 (1.08%) 1	

subjects affected / exposed occurrences (all)	7 / 90 (7.78%) 9	1 / 93 (1.08%) 1	
Investigations			
Blood creatinine increased subjects affected / exposed occurrences (all)	11 / 90 (12.22%) 15	8 / 93 (8.60%) 8	
Blood phosphorus decreased subjects affected / exposed occurrences (all)	37 / 90 (41.11%) 44	31 / 93 (33.33%) 41	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	44 / 90 (48.89%) 46	9 / 93 (9.68%) 11	
Weight decreased subjects affected / exposed occurrences (all)	8 / 90 (8.89%) 8	0 / 93 (0.00%) 0	
Blood bilirubin increased subjects affected / exposed occurrences (all)	3 / 90 (3.33%) 3	5 / 93 (5.38%) 7	
Creatinine renal clearance decreased subjects affected / exposed occurrences (all)	4 / 90 (4.44%) 5	5 / 93 (5.38%) 5	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	16 / 90 (17.78%) 18	10 / 93 (10.75%) 10	
Vertigo subjects affected / exposed occurrences (all)	12 / 90 (13.33%) 12	4 / 93 (4.30%) 4	
Memory impairment subjects affected / exposed occurrences (all)	5 / 90 (5.56%) 5	0 / 93 (0.00%) 0	
Blood and lymphatic system disorders			
Leukopenia subjects affected / exposed occurrences (all)	66 / 90 (73.33%) 90	24 / 93 (25.81%) 30	
Lymphopenia			



subjects affected / exposed	26 / 90 (28.89%)	12 / 93 (12.90%)	
occurrences (all)	29	13	
Neutropenia			
subjects affected / exposed	56 / 90 (62.22%)	14 / 93 (15.05%)	
occurrences (all)	71	14	
Thrombocytopenia			
subjects affected / exposed	31 / 90 (34.44%)	3 / 93 (3.23%)	
occurrences (all)	37	6	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 90 (7.78%)	5 / 93 (5.38%)	
occurrences (all)	8	5	
Abdominal pain upper			
subjects affected / exposed	13 / 90 (14.44%)	8 / 93 (8.60%)	
occurrences (all)	13	9	
Diarrhoea			
subjects affected / exposed	14 / 90 (15.56%)	4 / 93 (4.30%)	
occurrences (all)	16	4	
Dry mouth			
subjects affected / exposed	6 / 90 (6.67%)	0 / 93 (0.00%)	
occurrences (all)	6	0	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 90 (0.00%)	5 / 93 (5.38%)	
occurrences (all)	0	5	
Nausea			
subjects affected / exposed	10 / 90 (11.11%)	1 / 93 (1.08%)	
occurrences (all)	11	1	
Constipation			
subjects affected / exposed	6 / 90 (6.67%)	2 / 93 (2.15%)	
occurrences (all)	6	2	
Hepatobiliary disorders			
Hepatocellular injury			
subjects affected / exposed	55 / 90 (61.11%)	15 / 93 (16.13%)	
occurrences (all)	104	26	
Hyperbilirubinaemia			

subjects affected / exposed occurrences (all)	8 / 90 (8.89%) 8	3 / 93 (3.23%) 3	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	6 / 90 (6.67%) 6	1 / 93 (1.08%) 1	
Dry skin subjects affected / exposed occurrences (all)	10 / 90 (11.11%) 10	1 / 93 (1.08%) 1	
Pruritus subjects affected / exposed occurrences (all)	11 / 90 (12.22%) 13	2 / 93 (2.15%) 2	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	8 / 90 (8.89%) 9	3 / 93 (3.23%) 3	
Back pain subjects affected / exposed occurrences (all)	12 / 90 (13.33%) 13	5 / 93 (5.38%) 8	
Musculoskeletal pain subjects affected / exposed occurrences (all)	9 / 90 (10.00%) 9	2 / 93 (2.15%) 2	
Myalgia subjects affected / exposed occurrences (all)	20 / 90 (22.22%) 27	3 / 93 (3.23%) 3	
Muscle spasms subjects affected / exposed occurrences (all)	6 / 90 (6.67%) 6	3 / 93 (3.23%) 3	
Infections and infestations			
Influenza subjects affected / exposed occurrences (all)	7 / 90 (7.78%) 8	6 / 93 (6.45%) 6	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	16 / 90 (17.78%) 16	0 / 93 (0.00%) 0	

Vitamin D deficiency subjects affected / exposed occurrences (all)	8 / 90 (8.89%) 9	10 / 93 (10.75%) 10	
--	---------------------	------------------------	--

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 August 2010	The substantial modifications included in the amendment 1 of the protocol are: <ul style="list-style-type: none"><li>- Non-inclusion criterion;</li><li>- Change of the centre's principal investigator</li></ul>
14 December 2011	The substantial modifications included in amendment 2 of the protocol are: <ul style="list-style-type: none"><li>- Precision on the inclusion criterion;</li><li>- Extension of the inclusion period without change in follow-up in the main study;</li><li>- Addition of new investigator centres</li><li>- Change of the principal investigator of ANRS centre n°307 - La Pitié Salpêtrière</li><li>- Change of ANRS correspondent</li><li>- Change of pharmacovigilance correspondent</li><li>- Change in the distribution of the number of patients participating in the immunological sub-study</li><li>- Other minor changes (spelling, etc.)</li></ul>
09 May 2012	The substantial modifications included in amendment 3 of the protocol are: <ul style="list-style-type: none"><li>- Change of promoter</li><li>- Correction of the duration of the research</li></ul>
14 November 2012	The substantial modification included in amendment 4 of the protocol is the addition of a secondary objective.
31 January 2013	The substantial modification for information : modification of the number of patients randomised in the trial

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/28404133>